Search

Your search keyword '"GENERALIZED EPILEPSY"' showing total 58 results
Start Over Descriptor "GENERALIZED EPILEPSY" Database Supplemental Index
58 results on '"GENERALIZED EPILEPSY"'

1. Déjà vu in idiopathic generalized epilepsy: A systematic review.

Author

Alencar, Sarah Diógenes, Cendes, Fernando, de Morais, Alessandra Braga Cruz Guedes, Ribeiro, Vitoria Cristina Almeida Flexa, Frota, Norberto Anizio Ferreira, and Pinto, Lecio Figueira

Abstract

• Déjà Vu is classically associated with focal seizures originating from the medial temporal lobe. • 3 % of Idiopathic Generalized Epilepsy patients reported Déjà Vu (ranging from 0 to 11 % in the studies). Any type of aura was reported by 40 %. • Clinicians should recognize that Déjà Vu and other auras may experienced in Idiopathic generalized Epilepsy. • Recognizing this pitfall is crucial to avoiding diagnostic and treatment errors. Déjà vu (DV), a French term meaning "already seen," refers to inappropriate sensation of familiarity in the present moment, as if it had been experienced before without a specific recollection of when or where. Traditionally, DV has been closely associated with focal seizures originating from the medial temporal lobe. However, there are occasional reports of DV occurring in idiopathic generalized epilepsies (IGEs). The objective of our study was to assess the presence and frequency of DV in individuals with IGE. We used the Preferred Reporting Items for Systematic Review and Meta-Analysis for protocols (PRISMA-P) and searched PubMed and Embase from January 2000 to July 2022. 5 studies were included with a total of 1177 IGE and 1026 with temporal lobe epilepsy (TLE) patients. The frequency of DV in IGE ranged from 0 to 11 %, and the average was 3 %, compared to 19.6 % in TLE. Broadly, 40 % of patients with IGE reported some type of aura. EEG correlation of DV in IGE was not appropriately evaluated in the studies. Clinicians should be aware that individuals with IGE may experience DV and other types of auras. Recognizing these auras is crucial in order to avoid misdiagnosing IGE as focal epilepsy. This is important to prevent unnecessary investigations and incorrect treatment decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Psychiatric comorbidity in relation to clinical characteristics of epilepsy: A retrospective observational study.

Author

Revdal, Eline, Kolstad, Bjørn Patrick, Winsvold, Bendik Slagsvold, Selmer, Kaja Kristine, Morken, Gunnar, and Brodtkorb, Eylert

Abstract

• Prevalence of psychiatric comorbidity in epilepsy was 35%. • The prevalence was equal in focal and generalized epilepsy. • Unknown cause of focal epilepsy was significantly related to psychiatric disorders. • Comorbidity prevalence was independent of seizure control at last follow-up. • The rate of psychiatric disorders was high even in epilepsy resolved. Prevalence of psychiatric disorders in people with epilepsy is high. However, diagnostic validity and information about the nature of the seizure disorders are often poor in population-based studies. In a well validated and classified patient sample, we investigated psychiatric comorbidity according to clinical characteristics. Participants in The Trøndelag Health Study (HUNT) with ≥ 2 diagnostic epilepsy codes during 1987–2019 were identified. Medical records were reviewed, and epilepsy was validated and classified according to ILAE. Psychiatric comorbidity was defined by ICD-codes. In 448 individuals with epilepsy, 35% had at least one psychiatric disorder (anxiety and related disorders 23%, mood disorders 15%, substance abuse and personality disorders 7%, and psychosis 3%). Comorbidity was significantly higher in women than in men (p = 0.007). The prevalence of psychiatric disorders was 37% in both focal and generalized epilepsy. In focal epilepsy, it was significantly lower when etiology was structural (p = 0.011), whereas it was higher when the cause was unknown (p = 0.024). Comorbidity prevalence was 35% both in patients achieving seizure freedom and in those with active epilepsy but 38% among 73 patients with epilepsy resolved. Just over one third of people with epilepsy had psychiatric comorbidities. The prevalence was equal in focal and generalized epilepsy but was significantly higher in focal epilepsy of unknown cause compared to lesional epilepsy. Comorbidity was independent of seizure control at last follow-up but was slightly more common in those with resolved epilepsy, often having non-acquired genetic etiologies possibly linked to neuropsychiatric susceptibility. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. QT interval alterations in epilepsy: A thorough investigation between epilepsy subtypes.

Author

Gurses, Asli Akyol, Genc, Emine, Gurses, Kadri Murat, Altiparmak, Taylan, Yildirim, Irem, and Genc, Bulent Oguz

Abstract

• PWE had increased values of QTc and QTcd when compared to patients with PNESs. • QTc - QTcd values do not demonstrate any difference between patients with FE and GE. • PR interval is prolonged in PWE with left sided and extratemporal foci. Cardiac disturbances and rhythm abnormalities which potentially lead sudden unexpected death in epilepsy, have been extensively studied in focal epilepsies. However, studies including generalized epilepsies are scarce and it is not clear whether electrocardiogram parameters reflecting vulnerability to ventricular arrhythmias differ between these groups. Medical records of patients who were followed in epilepsy department of a tertiary center between October 2015 and September 2016 were retrospectively reviewed. 66 generalized and 64 focal epilepsy patients with eligible electrophysiological data were analyzed. QTc interval, QTcd and other electrocardiographic indices were compared between patients with focal vs generalized epilepsy. Another analysis was performed in order to disclose any difference between patients with epilepsy (n:130) and psychogenic non-epileptic seizures. A two-tailed p value < 0.05 was considered significant. There was no difference in terms of QTc and QTcd between patients with focal and generalized epilepsy [median: 406 ms vs 404 ms, p = 0.119; and median: 46 ms vs 44 ms, p = 0.497, respectively]. However patients with epilepsy were found to have longer QTc and QTcd when compared to ones with psychogenic non-epileptic seizures (p = 0.035 and p < 0.001, respectively). Current findings demonstrate that patients with epilepsy have longer QTc and QTcd than patients with pure psychogenic non-epileptic seizures. Since there was no difference between patients with focal and generalized epilepsy; QTc interval, QTcd and potential susceptibility to cardiac arrhythmias as a result, could be a consequence of epilepsy itself regardless of origin. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

5. Guangzhou University of Chinese Medicine Researchers Yield New Data on Generalized Epilepsy (Causality between ischemic stroke and epilepsy based on Mendelian randomization).

Abstract

Researchers at Guangzhou University of Chinese Medicine conducted a study to explore the causal relationship between ischemic stroke and epilepsy, specifically generalized epilepsy. Using Mendelian randomization analysis, they found a causal link between ischemic stroke and the risk of generalized epilepsy, but not focal epilepsy. The study also identified diastolic blood pressure and BMI as factors with a causal relationship to epilepsy risk. This research provides genetic evidence that can help stratify the risk of post-stroke epilepsy. [Extracted from the article]

Published
2024

7. Recent Findings from Mayo Clinic Has Provided New Information about Generalized Epilepsy (Centromedian Thalamic Deep Brain Stimulation for Idiopathic Generalized Epilepsy: Connectivity and Target Optimization).

Abstract

A recent study conducted at Mayo Clinic in Rochester, Minnesota has found that centromedian thalamic deep brain stimulation (CM-DBS) may be an effective treatment option for individuals with drug-resistant idiopathic generalized epilepsy (IGE). The study analyzed the targeting and efficacy of CM-DBS in five patients with drug-resistant IGE and found that the stimulation of the middle ventral CM nucleus resulted in the best outcomes. The researchers also discovered that the connectivity strength between the sweet-spot region and central peri-Rolandic cortex was significantly increased. These findings suggest that CM-DBS can be an effective treatment for patients with IGE and emphasize the importance of accurate targeting and analysis. [Extracted from the article]

Published
2024

8. Data on Generalized Epilepsy Reported by Researchers at University of Campinas (De<acute Accent>ja' Vu In Idiopathic Generalized Epilepsy: a Systematic Review).

Abstract

A systematic review conducted by researchers at the University of Campinas in Brazil explores the occurrence of déjà vu (DV) in individuals with idiopathic generalized epilepsies (IGEs). DV, a sensation of familiarity in the present moment, has traditionally been associated with focal seizures originating from the medial temporal lobe. However, this study found that DV can also occur in IGEs, although at a lower frequency compared to temporal lobe epilepsy (TLE). The researchers emphasize the importance of recognizing these auras in order to avoid misdiagnosing IGE as focal epilepsy and making incorrect treatment decisions. [Extracted from the article]

Published
2024

9. Study Data from New York University (NYU) Update Knowledge of Generalized Epilepsy (Idiopathic Generalized Epilepsy Misunderstandings, Challenges, and Opportunities).

Abstract

A recent study from New York University (NYU) highlights the misunderstandings, challenges, and opportunities surrounding idiopathic generalized epilepsy (IGE). The research reveals that IGE is often misdiagnosed as focal epilepsy, leading to underdiagnosis. It also emphasizes the need for improved diagnostic sensitivity and specificity, as well as better scientific understanding and therapies for IGE. The study concludes that IGE is an understudied condition with inadequate diagnostic and treatment options. [Extracted from the article]

Published
2024

10. Study Data from Guangzhou Medical University Provide New Insights into Generalized Epilepsy (Heterozygous Variants In Usp25 Cause Genetic Generalized Epilepsy).

Abstract

A study conducted by researchers at Guangzhou Medical University in China has identified a potential genetic cause for generalized epilepsy. The study focused on the USP25 gene, which encodes a protein involved in neural fate determination. Through whole exome sequencing, the researchers identified five variants in the USP25 gene in eight individuals affected by generalized seizures and/or febrile seizures. Functional tests in mice and in vitro experiments provided evidence that these variants can cause a form of generalized epilepsy with dominant inheritance. This research highlights the significance of USP25 heterozygous variants in epilepsy and emphasizes the critical role of USP25 in the brain. [Extracted from the article]

Published
2024

11. Reports Summarize Generalized Epilepsy Study Results from University of Melbourne [Huperzine a Suppresses Absence Seizures In the Genetic Absence Epilepsy Rat From Strasbourg (Gaers) Model of Genetic Generalized Epilepsy With Absence Seizures].

Abstract

A study conducted at the University of Melbourne in Australia evaluated the effectiveness of huperzine A in treating genetic generalized epilepsy (GGE) with absence seizures. The study found that huperzine A significantly reduced seizures in the 30-minute and 60-minute intervals after treatment, as well as during the cumulative 24-hour post-treatment period. The duration of action of huperzine A was shorter compared to ethosuximide, a positive control drug. The study suggests that huperzine A shows promise for clinical efficacy in GGE. [Extracted from the article]

Published
2024

12. LA EPILEPSIA MIOCLÓNICA JUVENIL Y LAS DISFUNCIONES NEUROCOGNITIVAS Y EJECUTIVAS ASOCIADAS.

Author

CAMPANILLE, VERÓNICA, SIERRA, NATALIA, CALLE, ANALÍA, BERNATER, RICARDO, THOMSON, ALEJANDRO, and O'NEILL, SANTIAGO

Abstract

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

13. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.

Author

Abdelmesih, Sherry Kodsy, Elkhateeb, Nour, Zakaria, Mostafa, and Girgis, Marian Y.

Abstract

Introduction: Levetiracetam (LEV) is a second-generation antiseizure medicine (ASM) with broad-spectrum efficacy and tolerability. Few studies have compared the efficacy of valproate (VPA) and LEV as monotherapy in the pediatric population. Herein, we compare the efficacy, tolerability and safety of LEV monotherapy with those of VPA monotherapy in ASM-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic (GTC) seizures.Methods: We retrospectively analyzed the clinical and electroencephalographic (EEG) data of these ASM-naïve pediatric patients who were treated with either oral VPA or oral LEV as monotherapy for over 2 years at our center.Results: This study included 60 patients with a seizure onset age between 2 months and 12 years. The patients on VPA (29 patients) and LEV monotherapy (31 patients) showed similar favorable 6-month treatment outcomes (complete seizure control in 79.31% vs 80.64%, p = 0.468052). Age at epilepsy onset, epilepsy syndrome, EEG features and ASM dose were not significant predictors of the 6-month treatment outcomes in either group. Lower seizure frequency at presentation was a predictor of favorable 6-month treatment outcomes in the LEV group but not in the VPA group. VPA and LEV treatment showed similar favorable 6-month treatment outcomes in the febrile seizures plus and patients with unidentified epilepsy syndrome subgroups. None of the patients discontinued VPA or LEV due to treatment-associated adverse effects.Discussion: Our study showed that compared to VPA monotherapy, LEV monotherapy in ASM-naïve infants and children with idiopathic generalized epilepsy with GTC seizures has a similarly favorable efficacy and tolerability, independent of age, EEG features and epilepsy syndrome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. Findings from Gheorghe Asachi Technical University Update Knowledge of Generalized Epilepsy (Enhanced Classification of Focal and Generalized Epilepsy Using Eemd and Ceemdan Methods).

Abstract

A research report from Gheorghe Asachi Technical University in Iasi, Romania discusses the development of a novel approach for classifying patients with focal and generalized epilepsy based on the analysis of EEG signals. The researchers used the Ensemble Empirical Mode Decomposition (EEMD) and Complete Ensemble Empirical Mode Decomposition with Adaptive Noise (CEEMDAN) techniques to extract features from the EEG signals. They then employed the K-nearest neighbors (KNN) and Naïve Bayes (NB) classifiers to accurately classify the signals into focal and generalized categories. The combination of the CEEMDAN-based approach and KNN classifier achieved a classification rate of 94.54%. The researchers aim to contribute to the development of effective and efficient diagnostic systems for epilepsy. [Extracted from the article]

Published
2024

15. New Findings from University of Catania in the Area of Generalized Epilepsy Published (Implications of a De Novo Variant in the SOX12 Gene in a Patient with Generalized Epilepsy, Intellectual Disability, and Childhood Emotional Behavioral...).

Abstract

A recent report from the University of Catania in Italy discusses new findings on generalized epilepsy. The research focuses on the SRY-box transcription factor (SOX) gene family, which plays a role in the development and neurogenesis of the nervous system. Through whole exome sequencing, a de novo variation was discovered in the SOX12 gene in a patient with generalized epilepsy, intellectual disability, and childhood emotional behavioral disorders. This variant is located in a critical functional site of the SOX12 protein and is predicted to have deleterious effects on protein structure. The study aims to establish a correlation between the SOX12 gene and the patient's symptoms. [Extracted from the article]

Published
2024

16. Research from Jilin University in the Area of Generalized Epilepsy Described (Causal relations between ischemic stroke and epilepsy: A bidirectional Mendelian randomization study).

Abstract

A recent study conducted by researchers at Jilin University in China explored the relationship between ischemic stroke (IS) and epilepsy. Using genetic data from the Genome-Wide Association Study (GWAS) database, the researchers found that IS was associated with an increased risk of developing epilepsy, particularly generalized epilepsy. However, no clear causal association was found between epilepsy and the onset of stroke. The study suggests that further investigation is needed to understand the mechanisms behind the effect of epilepsy on the pathogenesis of IS. [Extracted from the article]

Published
2024

17. Data from Guangzhou Medical University Provide New Insights into Generalized Epilepsy (Clinical Application of Trio-based Whole-exome Sequencing In Idiopathic Generalized Epilepsy).

Abstract

A recent study conducted by Guangzhou Medical University in China aimed to explore the genetic causes of idiopathic generalized epilepsies (IGEs). The researchers performed trio-based whole-exome sequencing on 60 cases of IGEs and identified seven candidate genetic variants. One variant in the SLC2A1 gene was determined to be pathogenic, while six other variants were considered causative after evaluation of clinical concordance. The study suggests that GABRB1 may be a novel causative gene for IGE and calls for further research on the topic. [Extracted from the article]

Published
2024

19. Mugla Sitki Kocman University Faculty of Medicine Researchers Describe Recent Advances in Generalized Epilepsy (Relationship Between Medication Adherence and Prospective Memory in Individuals with Epilepsy).

Abstract

Researchers from Mugla Sitki Kocman University Faculty of Medicine in Turkey conducted a study to examine medication adherence and prospective memory functions in individuals diagnosed with focal and generalized epilepsy. The study included 51 patients with focal epilepsy and 51 with generalized epilepsy. The researchers found no difference in prospective memory functions and medication adherence between the two groups. However, they did find near-significant correlations between medication adherence and memory function. The researchers concluded that more comprehensive studies are needed to further understand the relationship between memory and medication adherence in epilepsy. [Extracted from the article]

Published
2024

20. Centromedian thalamic deep brain stimulation for idiopathic generalized epilepsy: case series and target analysis.

Abstract

A recent study examined the use of centromedian thalamic deep brain stimulation (CM-DBS) as a potential treatment for drug-resistant idiopathic generalized epilepsy (IGE). The study included five patients with IGE who were treated with CM-DBS. The results showed that CM-DBS can be an effective treatment option for patients with IGE, with a median reduction in seizure frequency of 60%. The study also found that accurate targeting and volumetric analysis of the CM nucleus were important factors in achieving positive outcomes. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

Published
2024

21. New Generalized Epilepsy Data Have Been Reported by Investigators at Sapienza University of Rome (Topiramate Ban In Women of Childbearing Potential With Idiopathic Generalized Epilepsy: Does Effectiveness Offset the Teratogenic Risks?).

Abstract

A recent study conducted at Sapienza University of Rome investigated the effectiveness of topiramate (TPM) and levetiracetam (LEV) as first-line antiseizure medication in women of childbearing potential with idiopathic generalized epilepsy (IGE). The study found that women treated with TPM had higher risks of treatment failure and withdrawal, and were less likely to achieve seizure freedom at 12 months compared to women treated with LEV. The study suggests that there is a low tendency among clinicians to use TPM in this population, and the available data on effectiveness do not support its use. [Extracted from the article]

Published
2024

22. Seizure outcome during bilateral, continuous, thalamic centromedian nuclei deep brain stimulation in patients with generalized epilepsy: a prospective, open-label study.

Author

Cukiert, Arthur, Cukiert, Cristine Mella, Burattini, Jose Augusto, and Mariani, Pedro Paulo

Abstract

Objective: We report on the seizure frequency and attention outcome during thalamic centromedian stimulation (CM-DBS) in patients with refractory generalized epilepsy (GE).Methods: Twenty consecutive patients with GE who were submitted to CM-DBS and had at least one year of follow-up were prospectively studied. The CM was targeted bilaterally. Stimulation intensity was ramped up (bipolar, continuous, 130 Hz; 300μsec) until 4.5 V or until side effects developed. Contacts` position was determined on postoperative volumetric MRI scans. Attention was qualitatively evaluated using the SNAP-IV (Swanson, Nolan, and Pelham) questionnaire. Patients were considered responders during CM-DBS if an at least 50% seizure frequency reduction was obtained compared to baseline.Results: Median age was 15.5 years (13 males). Median follow-up time was 2.55 years. EEG disclosed generalized spike-and wave discharges in all patients. MRI was normal in 10 patients, showed diffuse atrophy in 6 patients, and showed abnormalities in 4 patients (3 patients had bilateral cortical development abnormalities and one had unilateral hemispheric atrophy). Patients presented with daily multiple seizure types (8 to 66 per day; median: 37), including tonic, atonic, myoclonic, atypical absence and generalized tonic-clonic seizures. Mean DBS intensity was 4.3 V. An insertional effect was noted in 14 patients. CM-DBS was able to significantly reduce the frequency of tonic (p < 0.001), atypical absence seizures (p < 0.001), atonic seizures (p = 0.001) and bilateral generalized tonic-clonic seizures (p = 0.004). One patient became seizure-free. Ninety percent of the patients were considered responders (>50% seizure frequency reduction). All patients showed some improvement in attention. The mean number of items in which improvement was noted in the SNAP-IV questionnaire was 4.8. There was a significant relationship between overall seizure frequency reduction and improvement of attention (p = 0.033).Discussion: This prospective, open label study included a large, homogeneous cohort and provided evidence on the efficacy of CM-DBS in reducing the seizure burden and increasing attention in patients with refractory generalized epilepsy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Epileptic seizure semiology in infants and children.

Author

Park, Jun T. and Fernandez-Baca Vaca, Guadalupe

Abstract

Epileptic seizure semiology adds important information to the formulation of the hypothesis of the epileptogenic zone. Seizure semiology in infants and children are simple and elementary, becoming more complex with maturation of brain. Also in this age group, seizure semiology may be generalized in a setting of a focal lesion or may show focal signs with misleading localization values. We review seizure semiology of patients aged one month to ten years with respect to lateralization and localization of the epileptogenic zone. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Focal EEG abnormalities and focal ictal semiology in generalized epilepsy.

Author

Fernandez-Baca Vaca, G. and Park, Jun T.

Abstract

In clinical practice, the diagnosis of focal vs generalized epilepsy dictates the management of the patient. The distinction between generalized and focal epilepsy is at times imperfect and some epilepsies have features that fall in between these two extremes. An example is the occurrence of focal interictal and focal ictal abnormalities in generalized epilepsies. As a part of the special issue on "The epileptogenic zone in pediatric epilepsy surgery", this focused narrative review will discuss different focal abnormalities seen in generalized epilepsy. An overlap of focal and generalized epileptiform abnormalities may support a continuum between focal and generalized epilepsy. When evaluating patients in the "gray zone", other factors such as ictal semiology, neuroimaging, genetic testing and functional deficits may need to be considered to reach an accurate diagnosis. Being aware of possible occurrence of focal clinical and EEG features in generalized epilepsy will help clinicians select more preferred AED (s), avoiding potential iatrogenic side effects and inappropriate consideration for epilepsy surgery. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. CAMBIOS ESTRUCTURALES CEREBRALES EN EPILEPSIA GENERALIZADA IDIOPÁTICA IDENTIFICADOS POR ANÁLISIS DE IMÁGENES DE RESONANCIA MAGNÉTICA AUTOMATIZADOS.

Author

CARLOS AVALOS, JUAN, SÁNCHEZ, FRANCISCO, ROSSO, BARBARA, GABRIELA BESOCKE, ANA, and DEL CARMEN GARCÍA, MARÍA

Abstract

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

27. Researchers at University of Electronic Science and Technology of China Have Reported New Data on Generalized Epilepsy (The Role of the Primary Sensorimotor System In Generalized Epilepsy: Evidence From the Cerebello-cerebral Functional...).

Abstract

A recent study conducted by researchers at the University of Electronic Science and Technology of China explores the role of the primary sensorimotor system in generalized epilepsy. The study examines the functional interaction between the cerebellum and cerebrum and reveals altered mapping of cerebral motor components to the cerebellum in patients with idiopathic generalized epilepsy. The findings suggest that the cerebral primary motor system influences the hierarchical architecture of the cerebellum and contributes to motor functional abnormalities in epilepsy patients. This research provides valuable insights into the collaborative processing of sensorimotor information in epilepsy patients. [Extracted from the article]

Published
2024

28. Researchers from Fourth Military Medical University Publish Findings in Generalized Epilepsy (Status epilepticus in patients with genetic generalized epilepsy: a case series study).

Abstract

A recent study conducted by researchers from Fourth Military Medical University in China focused on status epilepticus (SE) in patients with genetic generalized epilepsy (GGE). The study included nine patients with GGE, with the majority being female. The researchers analyzed the demographic and clinical characteristics of the patients, as well as the SE patterns and termination methods. The study found that the seizure type of SE in patients with GGE is often consistent with their major symptoms, and oral midazolam may be an option to terminate SE in these patients. The findings provide valuable insights into the understanding and management of SE in individuals with GGE. [Extracted from the article]

Published
2024

29. Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.

Abstract

A recent study investigated the use of polygenic risk scores (PRSs) as biomarkers for epilepsy risk. The study analyzed the electronic health records of over 360,000 individuals in Finland over a span of up to 50 years. The results showed that individuals with a high genetic generalized epilepsy PRS had an increased risk for genetic generalized epilepsy (GGE) across their lifetime and after unspecified seizure events. The study also found that the effects of PRSs were larger in females and younger age groups. These findings suggest that PRSs could potentially serve as biomarkers for epilepsy diagnosis. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

Published
2023

30. Research Findings from Liaoning Update Understanding of Generalized Epilepsy (Idiopathic generalized epilepsy with phantom absences, absence status, and generalized tonic-clonic seizures: A case report).

Abstract

A case report from Liaoning, People's Republic of China, discusses a rare condition called idiopathic generalized epilepsy with phantom absences, absence status, and generalized tonic-clonic seizures. The report describes the case of a 31-year-old woman who presented with a 16-year history of seizures. The patient was diagnosed with idiopathic generalized epilepsy based on electroencephalogram (EEG) findings and was successfully treated with oral sodium valproate. The report concludes that EEG is the key diagnostic method for this condition and that antiepileptic drugs are effective in controlling seizures. [Extracted from the article]

Published
2023

32. New Generalized Epilepsy Findings Has Been Reported by Investigators at University of Tennessee (Effectiveness, Safety and Tolerability of Perampanel By Age Group When Used To Treat People With Focal and Generalized Epilepsy In Clinical...).

Abstract

In the overall population, retention rates at 3, 6, and 12 months were 88.0%, 77.6%, and 61.4%, respectively; responder rates at 12 months were 58.5% for total seizures, 54.6% for focal seizures, and 77.7% for generalized seizures, and corresponding seizure freedom rates were 23.6%, 19.0%, and 51.3%, respectively. Keywords: Memphis; State:Tennessee; United States; North and Central America; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Generalized Epilepsy; Health and Medicine; Nervous System Diseases and Conditions; Neurologic Manifestations; Seizures EN Memphis State:Tennessee United States North and Central America Brain Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Generalized Epilepsy Health and Medicine Nervous System Diseases and Conditions Neurologic Manifestations Seizures 665 665 1 11/06/23 20231106 NES 231106 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators discuss new findings in Central Nervous System Diseases and Conditions - Generalized Epilepsy. [Extracted from the article]

Published
2023

33. Research from Sapienza University of Rome in Generalized Epilepsy Provides New Insights (Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy).

Abstract

Brain Diseases and Conditions, Central Nervous System Agents, Central Nervous System Diseases and Conditions, Drugs and Therapies, Epilepsy, Health and Medicine, Lamotrigine Therapy, Levetiracetam Therapy, Pharmaceuticals, Pyrrolidine Anticonvulsants, Triazine Anticonvulsants, Generalized Epilepsy Keywords: Brain Diseases and Conditions; Central Nervous System Agents; Central Nervous System Diseases and Conditions; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Health and Medicine; Lamotrigine Therapy; Levetiracetam Therapy; Pharmaceuticals; Pyrrolidine Anticonvulsants; Triazine Anticonvulsants EN Brain Diseases and Conditions Central Nervous System Agents Central Nervous System Diseases and Conditions Drugs and Therapies Epilepsy Generalized Epilepsy Health and Medicine Lamotrigine Therapy Levetiracetam Therapy Pharmaceuticals Pyrrolidine Anticonvulsants Triazine Anticonvulsants 1811 1811 1 10/16/23 20231020 NES 231020 2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on generalized epilepsy have been published. [Extracted from the article]

Published
2023

34. Findings from Odense University Hospital Broaden Understanding of Generalized Epilepsy (Neuropsychological Profile and Drug Treatment Response In Idiopathic Generalized Epilepsy).

Abstract

Odense, Denmark, Europe, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Drugs and Therapies, Epilepsy, Generalized Epilepsy, Health and Medicine Keywords: Odense; Denmark; Europe; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Health and Medicine EN Odense Denmark Europe Brain Diseases and Conditions Central Nervous System Diseases and Conditions Drugs and Therapies Epilepsy Generalized Epilepsy Health and Medicine 224 224 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on Central Nervous System Diseases and Conditions - Generalized Epilepsy. [Extracted from the article]

Published
2023

35. Defective interhemispheric inhibition in drug-treated focal epilepsies.

Author

Strigaro, Gionata, Matino, Erica, Falletta, Lina, Pizzamiglio, Chiara, Tondo, Giacomo, Badawy, Radwa, and Cantello, Roberto

Abstract

Background Focal epilepsies (FEs) arise from a lateralized network, while in generalized epilepsies (GEs) there is a bilateral involvement from the outset. Intuitively, the corpus callosum is the anatomical substrate for interhemispheric spread. Objective We used transcranial magnetic stimulation (TMS) to explore whether there are any physiological differences in the corpus callosum of drug-treated patients with FE and those with genetic GE (GGE), compared to healthy subjects (HS). Methods TMS was used to measure the interhemispheric inhibition (IHI) from right-to-left primary motor cortex (M1) and viceversa in 16 patients with FE, 17 patients with GGE and 17 HS. A conditioning stimulus (CS) was given to one M1 10 and 50 ms before a test stimulus delivered to the contralateral M1. Motor evoked potentials (MEPs) were analysed both as a function of the side of stimulation and of the epileptic focus (left-right). Results In HS, IHI was reproducible with suppression of MEPs at ISIs of 10 and 50 ms. Similar effects occurred in GGE patients. FE patients behaved differently, since IHI was significantly reduced bilaterally. When FE patients were stratified according to the side of their epileptic focus, the long-ISI IHI (=50 ms) appeared to be defective only when the CS was applied over the “focal” hemisphere. Conclusions FE patients had a defective inhibitory response of contralateral M1 to inputs travelling from the “focal” hemisphere that was residual to the drug action. Whilst IHI changes would not be crucial for the GGE pathophysiology, they may represent one key factor for the contralateral spread of focal discharges, and seizure generalization. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. Absence epilepsy: Continuum of clinical presentation and epigenetics?

Author

Guilhoto, Laura M.

Abstract

Purpose: Although absence seizures do predominate in childhood they may occur at all ages and clinical presentation varies widely. Albeit considered a benign seizure type, chronic evolution with therapeutic refractoriness is possible in some patients with absences. The aim of this paper is to summarize the main syndromic presentation of absence seizures and its outcome regarding treatment and prognosis.Method: We performed a review of literature with emphasis in historic and classical manuscripts about absence epilepsy.Results: Absence was described in the beginning of last century as a seizure type with good evolution, but it is still difficult to preview a strict prognosis for an individual patient. Some positive early predictors were reported such as response to initial treatment and seizure onset in childhood. Genetic aspects are not yet well understood although some families have been reported with rare mutations in ion channel coding genes.Conclusion: Absence seizures are present in different epilepsy syndromes and nosological classification is not always possible. Outcome depends on clinical variables such as age of onset, presence of other seizure types and initial response to treatment. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

37. Marmara University Researchers Advance Knowledge in Generalized Epilepsy (Evaluation of the Effect of Anti-seizure Drugs on Cognition in Patients with Idiopathic Generalized Epilepsy by Digital Neuropsychological Test).

Abstract

Keywords: Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Health and Medicine EN Brain Diseases and Conditions Central Nervous System Diseases and Conditions Drugs and Therapies Epilepsy Generalized Epilepsy Health and Medicine 1064 1064 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on generalized epilepsy are discussed in a new report. Keywords for this news article include: Marmara University, Istanbul, Turkey, Eurasia, Drugs and Therapies, Health and Medicine, Generalized Epilepsy, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions. Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Drugs and Therapies, Epilepsy, Health and Medicine, Generalized Epilepsy. [Extracted from the article]

Published
2023

38. Researchers at Gottingen University Medical Center Target Generalized Epilepsy (Multi-spectral diffusion MRI mega-analysis in genetic generalized epilepsy: Relation to outcomes).

Abstract

Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Epilepsy, Generalized Epilepsy, Genetics, Health and Medicine Keywords: Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine EN Brain Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Generalized Epilepsy Genetics Health and Medicine 1056 1056 1 07/24/23 20230728 NES 230728 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Researchers detail new data in generalized epilepsy. [Extracted from the article]

Published
2023

39. Research from First Affiliated Hospital of Wenzhou Medical University in the Area of Generalized Epilepsy Published (The impact of serum copper on the risk of epilepsy: a mendelian randomization study).

Abstract

Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Epilepsy, Genetics, Health and Medicine, Risk and Prevention, Generalized Epilepsy Keywords: Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine; Risk and Prevention EN Brain Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Generalized Epilepsy Genetics Health and Medicine Risk and Prevention 1197 1197 1 07/10/23 20230714 NES 230714 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Research findings on generalized epilepsy are discussed in a new report. [Extracted from the article]

Published
2023

40. Findings from Gladstone Institute of Neurological Disease Update Understanding of Generalized Epilepsy (Thalamocortical Circuits In Generalized Epilepsy: Pathophysiologic Mechanisms and Therapeutic Targets).

Abstract

According to the news reporters, the research concluded: "Elucidating the role of the thalamus in generalized epilepsy syndromes may lead to new opportunities to better treat pharmaco-resistant generalized epilepsy by thalamic modulation and dietary therapy." San Francisco, State:California, United States, North and Central America, Brain, Brain Diseases and Conditions, Central Nervous System, Central Nervous System Diseases and Conditions, Diencephalon, Drugs and Therapies, Epilepsy, Generalized Epilepsy, Health and Medicine, Thalamus Keywords: San Francisco; State:California; United States; North and Central America; Brain; Brain Diseases and Conditions; Central Nervous System; Central Nervous System Diseases and Conditions; Diencephalon; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Health and Medicine; Thalamus EN San Francisco State:California United States North and Central America Brain Brain Diseases and Conditions Central Nervous System Central Nervous System Diseases and Conditions Diencephalon Drugs and Therapies Epilepsy Generalized Epilepsy Health and Medicine Thalamus 509 509 1 06/05/23 20230609 NES 230609 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Central Nervous System Diseases and Conditions - Generalized Epilepsy. [Extracted from the article]

Published
2023

42. Investigators at Mayo Clinic Report Findings in Generalized Epilepsy (Is Thalamic Deep Brain Stimulation Synergistic With Vagus Nerve Stimulation In Drug-resistant Genetic Generalized Epilepsy?).

Abstract

Keywords: Jacksonville; State:Florida; United States; North and Central America; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Drug Resistance; Drugs and Therapies; Electric Stimulation Therapy; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine; Medical Devices; Vagus Nerve Stimulation EN Jacksonville State:Florida United States North and Central America Brain Diseases and Conditions Central Nervous System Diseases and Conditions Drug Resistance Drugs and Therapies Electric Stimulation Therapy Epilepsy Generalized Epilepsy Genetics Health and Medicine Medical Devices Vagus Nerve Stimulation 821 821 1 05/29/23 20230602 NES 230602 2023 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Central Nervous System Diseases and Conditions - Generalized Epilepsy are presented in a new report. According to news originating from Jacksonville, Florida, by NewsRx correspondents, research stated, "Neuromodulation in epilepsy is a proven treatment for people with drug-resistant focal epilepsy. [Extracted from the article]

Published
2023

43. New Generalized Epilepsy Findings from Tabriz University of Medical Sciences Described [The Study of Rs324420 (C385a) Polymorphism of the Faah Gene of the Endocannabinoid System In Patients With Epilepsy and Adhd].

Abstract

Tabriz, Iran, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Epilepsy, Generalized Epilepsy, Genetics, Health and Medicine, Risk and Prevention The news reporters obtained a quote from the research from the Tabriz University of Medical Sciences, "Single nucleotide polymorphism (SNP) rs324420 is a common genetic polymorphism of the FAAH gene and has been associated with susceptibility to neurological conditions. Keywords: Tabriz; Iran; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine; Risk and Prevention EN Tabriz Iran Brain Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Generalized Epilepsy Genetics Health and Medicine Risk and Prevention 745 745 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Researchers detail new data in Central Nervous System Diseases and Conditions - Generalized Epilepsy. [Extracted from the article]

Published
2023

44. Studies in the Area of Generalized Epilepsy Reported from Baylor University College of Medicine (Neurostimulation In Generalized Epilepsy: a Systematic Review and Meta-analysis).

Abstract

Keywords: Houston; State:Texas; United States; North and Central America; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Generalized Epilepsy; Health and Medicine EN Houston State:Texas United States North and Central America Brain Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Generalized Epilepsy Health and Medicine 913 913 1 04/10/23 20230414 NES 230414 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on Central Nervous System Diseases and Conditions - Generalized Epilepsy is the subject of a report. Houston, State:Texas, United States, North and Central America, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Epilepsy, Generalized Epilepsy, Health and Medicine. [Extracted from the article]

Published
2023

45. Fayoum University Researchers Have Published New Data on Generalized Epilepsy (Could thalamic biochemical changes correlate to cognitive impairment in idiopathic generalized epilepsy?).

Abstract

Keywords for this news article include: Fayoum University, Thalamus, Biochemicals, Biochemistry, Diencephalon, Health and Medicine, Generalized Epilepsy, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions. Keywords: Biochemicals; Biochemistry; Brain; Brain Diseases and Conditions; Central Nervous System; Central Nervous System Diseases and Conditions; Chemicals; Diencephalon; Epilepsy; Generalized Epilepsy; Health and Medicine; Thalamus EN Biochemicals Biochemistry Brain Brain Diseases and Conditions Central Nervous System Central Nervous System Diseases and Conditions Chemicals Diencephalon Epilepsy Generalized Epilepsy Health and Medicine Thalamus 201 201 1 04/03/23 20230403 NES 230403 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Researchers detail new data in generalized epilepsy. [Extracted from the article]

Published
2023

46. New Findings from Medical College of Wisconsin Describe Advances in Generalized Epilepsy (Responsive Neurostimulation of the Anterior Thalamic Nuclei in Refractory Genetic Generalized Epilepsy: A Case Series).

Abstract

Anterior Thalamic Nuclei, Brain Diseases and Conditions, Brain Research, Central Nervous System, Central Nervous System Diseases and Conditions, Diencephalon, Drug Resistance, Drugs and Therapies, Epilepsy, Genetics, Health and Medicine, Prosencephalon, Generalized Epilepsy Keywords: Anterior Thalamic Nuclei; Brain Diseases and Conditions; Brain Research; Central Nervous System; Central Nervous System Diseases and Conditions; Diencephalon; Drug Resistance; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine; Prosencephalon EN Anterior Thalamic Nuclei Brain Diseases and Conditions Brain Research Central Nervous System Central Nervous System Diseases and Conditions Diencephalon Drug Resistance Drugs and Therapies Epilepsy Generalized Epilepsy Genetics Health and Medicine Prosencephalon 2023 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Current study results on generalized epilepsy have been published. [Extracted from the article]

Published
2023

47. When should clinicians search for GLUT1 deficiency syndrome in childhood generalized epilepsies?

Author

Lebon, Sébastien, Suarez, Philippe, Alija, Semsa, Korff, Christian M., Fluss, Joël, Mercati, Danielle, Datta, Alexandre N., Poloni, Claudia, Marcoz, Jean-Pierre, Campos-Xavier, Ana Belinda, Bonafé, Luisa, and Roulet-Perez, Eliane

Abstract

GLUT1 deficiency (GLUT1D) has recently been identified as an important cause of generalized epilepsies in childhood. As it is a treatable condition, it is crucial to determine which patients should be investigated. Methods We analyzed SLC2A1 for mutations in a group of 93 unrelated children with generalized epilepsies. Fasting lumbar puncture was performed following the identification of a mutation. We compared our results with a systematic review of 7 publications of series of patients with generalized epilepsies screened for SLC2A1 mutations. Results We found 2/93 (2.1%) patients with a SLC2A1 mutation. One, carrying a novel de novo deletion had epilepsy with myoclonic-atonic seizures (MAE), mild slowing of head growth, choreiform movements and developmental delay. The other, with a paternally inherited missense mutation, had childhood absence epilepsy with atypical EEG features and paroxysmal exercise-induced dyskinesia (PED) initially misdiagnosed as myoclonic seizures. Out of a total of 1110 screened patients with generalized epilepsies from 7 studies, 2.4% (29/1110) had GLUT1D. This rate was higher (5.6%) among 303 patients with early onset absence epilepsy (EOAE) from 4 studies. About 50% of GLUT1D patients had abnormal movements and 41% a family history of seizures, abnormal movements or both. Conclusion GLUT1D is most likely to be found in MAE and in EOAE. The probability of finding GLUT1D in the classical idiopathic generalized epilepsies is very low. Pointers to GLUT1D include an increase in seizures before meals, cognitive impairment, or PED which can easily be overlooked. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

48. Study Findings from Cairo University Broaden Understanding of Generalized Epilepsy (Genetic generalized epilepsy: factors associated with drug resistance polytherapy).

Abstract

Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Drug Resistance, Drugs and Therapies, Epilepsy, Generalized Epilepsy, Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurologic Manifestations, Seizures Keywords: Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Drug Resistance; Drugs and Therapies; Epilepsy; Generalized Epilepsy; Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurologic Manifestations; Seizures EN Brain Diseases and Conditions Central Nervous System Diseases and Conditions Drug Resistance Drugs and Therapies Epilepsy Generalized Epilepsy Genetics Health and Medicine Nervous System Diseases and Conditions Neurologic Manifestations Seizures 2023 FEB 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on generalized epilepsy have been presented. [Extracted from the article]

Published
2023

49. Ketogenic diet in adolescents and adults with epilepsy.

Author

Nei, Maromi, Ngo, Ly, Sirven, Joseph I., and Sperling, Michael R.

Abstract

Abstract: Purpose: The ketogenic diet is an alternative treatment for patients with refractory epilepsy. Most studies to date report dietary response in children. There are limited data evaluating the efficacy of the ketogenic diet in adults. This is a report of the long-term outcome in a largely adult population of patients treated with the ketogenic diet for epilepsy. Method: Twenty-nine adult and adolescent patients (mean age 32 years, range 11–51) were initiated on the ketogenic diet and followed until diet discontinuation. Clinical response and adverse effects were noted during the duration of the diet. Results: Fifty-two percent of patients had a significant reduction in seizure frequency on the ketogenic diet, including 45% with ≥50% reduction in seizure frequency. Thirty-one percent had no improvement, seven percent were unable to successfully initiate the diet, and 10% had a >50% increase in seizure frequency. The diet was continued for a mean of 9 months (range 0.13–35 months), with five patients completing ≥23 months. There was a trend toward better response and better tolerability/longer duration in patients with symptomatic generalized epilepsy. The diet was generally well-tolerated, but undesired weight loss and constipation were the most frequent adverse effects. Conclusion: The ketogenic diet can be used safely in the adult and adolescent population, with a response rate similar to those seen in children. Patient with symptomatic generalized epilepsy may be particularly good candidates for this type of dietary treatment. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

50. Epilepsy syndromes of childhood and adolescence.

Author

McTague, Amy

Abstract

Abstract: Epilepsy syndromes are defined as distinctive disorders identifiable on the basis of a typical age of onset, specific EEG characteristics, seizure types, and other features. A wide range of epilepsy syndromes present throughout infancy, childhood and adolescence from benign self-limiting syndromes to severe epileptic encephalopathies. Accurate recognition and diagnosis of these syndromes is essential to ensure appropriate investigation and treatment. Recent revisions to the classification of childhood epilepsy and recent scientific, particularly genetic, discoveries have had an impact on our understanding of the childhood epilepsies. In this review we consider the role of syndromic diagnosis and describe the typical features and presentation of the most important epilepsy syndromes of childhood and adolescence. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results